Progressive supranuclear palsy: Staring into the past, moving into the future

Neurologist

Volumn 4, Issue 1, 1998, Pages 13-20

  Litvan, Irene ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Neurodegenerative disorders; Pathogenesis; Progressive supranuclear palsy; Therapies

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; AMITRIPTYLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; EFAROXAN; FLUORODEOXYGLUCOSE F 18; IDAZOXAN; IODINE 123; LEVODOPA; PHYSOSTIGMINE;

DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DYSPHAGIA; EVENT RELATED POTENTIAL; GAIT DISORDER; HUMAN; NEUROLOGIC DISEASE; NEUROTRANSMISSION; OPHTHALMOPLEGIA; PALLIATIVE THERAPY; PARKINSONISM; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031910804     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199801000-00003     Document Type: Review

References (96)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10:333-59.
2. Lees AJ. Foreward. In: Litvan I, Agid Y, editors. Progressive supranuclear palsy: Clinical and research approaches. New York: Oxford University Press, 1992:vi-x.
3. Brusa A, Peloso PF, editors. An introduction to progressive supranuclear palsy. Rome: J Libbey; 1993.
4. Tolosa E, Duvoisin R, Cruz-Sanchez FF, editors. Progressive supranuclear palsy: Diagnosis, pathology, and therapy. Supplementum 42. Wien: Springer-Verlag, 1994.
5. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: A clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615-20.
6. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-9.
7. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38: 1031-4.
8. Nuwer M. Progressive supranuclear palsy despite normal eye movements. Arch Neurol 1981;38:784.
9. Dubas F, Gray F, Escourolle R. Maladie de Steele-Richardson-Olszewski sans ophthalmoplegie. Rev Neurol 1983;139:407-16.
10. Matsuo H, Takashima H, Kishikawa M, et al. Pure akinesia: An atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991;54:397-400.
11. Riley DE, Fogt N, Leigh RJ. The syndrome of 'pure akinesia' and its relationship to progressive supranuclear palsy. Neurology 1994;44: 1025-9.
12. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psychiatry 1991;54:159-61.
13. De Bruin VM, Lees AJ, Daniel SE. Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report. Mov Disord 1992;7:355-8.
14. Foster NL, Gilman S, Berent S, et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry 1992;55:707-13.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
16. Revesz T, Daniel SE, Lees AJ, Will RG. A case of progressive subcortical gliosis associated with deposition of abnormal prion protein. J Neurol Neurosurg Psychiatry 1995;58:759-60.
17. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele Richardson-Olszewski syndrome). Neurology 1996;46:922-30.
18. Siderowf AD, Galetta SL, Hurtig HI, Liu GT. Posey, Spiller and progressive supranuclear palsy: An incorrect attribution [abstract]. Neurology 1997;48:A623.
19. Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997;120:65-74.
20. Colosimo C, Albanese A, Hughes AJ, de Bruin VM, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-8.
21. Rivest J, Quinn N, Marsden CD. Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurology 1990;40:1571-8.
22. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997;62:352-6.
23. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
24. Rottach KG, Riley DE, DiScenna AO, Zivotofsky AZ, Leigh RJ. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 1996;39:368-77.
25. Quinn N. The "round the houses" sign in progressive supranuclear palsy [letter]. Ann Neurol 1996;40:951.
26. Golbe LI, Davis PH, Lepore FE. Eyelid movement abnormalities in progressive supranuclear palsy. Mov Disord 1989;4:297-302.
27. Friedman DI, Jankovic J, McCrary JA. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol 1992; 12:104-9.
28. Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. J Neural Transm Suppl 1994;42:33-41.
29. Kluin KJ, Foster NL, Berent S, Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology 1993; 43:563-6.
30. Litvan I, Sastry N, Sonies BC. Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology 1997;48:1654-62.
31. Johnston BT, Castell JA, Stumacher S, et al. Comparison of swallowing function in Parkinson's disease and progressive supranuclear palsy. Mov Disord 1997;12:323-7.
32. Robbins TW, James M, Owen AM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57:79-88.
33. Pillon B, Gouider-Khouja N, Deweer B, et al. Neuropsychological pattern of striatonigral degeneration: Comparison with Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995;58:174-9.
34. Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry 1985;48:1234-9.
35. Grafman J, Litvan I, Gomez C, Chase TN. Frontal lobe function in progressive supranuclear palsy. Arch Neurol 1990;47:553-8.
36. Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991;41:634-43.
37. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1997;47:1184-9.
38. Esmonde T, Giles E, Xuereb J, Hodges J. Progressive supranuclear palsy presenting with dynamic aphasia. J Neurol Neurosurg Psychiatry 1996;60:403-10.
39. Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: A clinicopathological study of 21 cases. Acta Neuropathol (Berl) 1996;91:427-31.
40. Litvan I, Grafman J, Gomez C, Chase T. Memory impairment in patients with progressive supranuclear palsy. Arch Neurol 1989;46:765-7.
41. Pillon B, Deweer D, Michon A, Malapani C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 1994;44:1264-70.
42. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-24.
43. Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: Comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995;45:1477-83.
44. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997;120:75-90.
45. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-6.
46. Wenning G, Ben Shlomo Y, Magalhaes M, Daniel S, Quinn N. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835-45.
47. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: A review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.
48. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994;35:420-6.
49. Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy: A comparison with Parkinson's disease. Arch Neurol 1988;45:1194-9.
50. Johnson RJ, Litvan I, Grafman J. Progressive supranuclear palsy: Altered sensory processing leads to degraded cognition. Neurology 1991;41:1257-62.
51. Johnson RJ. Event-related brain potentials. In: Litvan I, Agid Y, editors. Progressive supranuclear palsy: Clinical and research approaches. New York: Oxford University Press, 1992:122-54.
52. Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 1994;42:93-110.
53. Yagishita A, Oda M. Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 1996;38(Suppl 1):S60-6.
54. Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997;62:239-42.
55. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120:1541-52.
56. D'Antona R, Baron JC, Samson Y, et al. Subcortical dementia: Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985;108:785-99.
57. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24:399-406.
58. Blin J, Horwitz B, Baron J, Agid Y. Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction? Eur J Neurol 1995;1:221-8.
59. 76Br] bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 1986;6:131-6.
60. Leenders KL, Frackowiak RS, Lees AJ. Steele-Richardson-Olszewski syndrome: Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 1988;111: 615-30.
61. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
62. Brooks DJ. PET studies in progressive supranuclear palsy. J Neural Transm Suppl 1994;42:119-34.
63. Agid Y, Javoy-Agid F, Ruberg M, et al. Progressive supranuclear palsy: Anatomoclinical and biochemical considerations. Adv Neurol 1987;45:191-206.
64. Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy: Clinicopathological data in 10 cases. Brain 1996;119:1123-36.
65. Yamauchi H, Fukuyama H, Nagahama Y, et al. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy. Ann Neurol 1997;41:606-14.
66. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA 1997;94:4113-8.
67. Litvan I. Parkinsonism-dementia syndromes. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 3rd ed. Baltimore: Williams & Wilkins. In press.
68. Geddes JF, Hughes AJ, Lees AJ, Daniel SE. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles: A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 1993;116:281-302.
69. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
70. Takahashi T, Amano N, Hanihara T, et al. Corticobasal degeneration: widespread argentophilic threads and glia in addition to neurofibrillary tangles: Similarities of cytoskeletal abnormalities in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci 1996;138:66-77.
71. Litvan I, DeLeo JM, Hauw JJ, et al. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features? Brain 1996;119:831-9.
72. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996;55:53-67.
73. Malessa S, Hirsch EC, Cervera P, Duyckaerts C, Agid Y. Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: A quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration. Neurology 1990;40:1739-43.
74. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991;41:25-30.
75. 67 messenger RNA. Neurology 1995;45:127-34.
76. Litvan I, Chase TN. Traditional and experimental therapeutic approaches. In: Litvan I, Agid Y, editors. Progressive supranuclear palsy: Clinical and research approaches. New York: Oxford University Press, 1992:254-69.
77. Hardman CD, Halliday GM, McRitchie DA, Cartwright HR, Morris JG. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol 1997;144:183-92.
78. Hardman CD, Halliday GM, McRitchie DA, Morris JG. The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy. J Neuropathol Exp Neurol 1997;56:132-42.
79. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989;39:257-61.
80. Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989;26:404-7.
81. Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55-61.
82. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41:986-91.
83. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: A review of 264 patients. J Neurol Neurosurg Psychiatry 1988;51:767-72.
84. Jankovic J. Progressive supranuclear palsy: Clinical and pharmacologic update. Neurol Clin 1984;2:473-86.
85. Agid Y. Conclusions. In: Litvan I, Agid Y, editors. Progressive supranuclear palsy: Clinical and research approaches. New York: Oxford University Press, 1992:270-3.
86. Jellinger KA, Bancher C. Neuropathology. In: Litvan I, Agid Y, eds. Progressive supranuclear palsy: Clinical and research approaches. New York: Oxford University Press, 1992:44-88.
87. Villares J, Strada O, Faucheux B, Javoy-Agid F, Agid Y, Hirsch EC. Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease. Neurosci Lett 1994;182:59-62.
88. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277-81.
89. Tetrud JW, Golbe LI, Forno LS, Farmer PM. Autopsy-proven progressive supranuclear palsy in two siblings. Neurology 1996;46:931-4.
90. Tabaton M, Rolleri M, Masturzo P, et al. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy. Neurology 1995;45:1764-5.
91. Anouti A, Schmidt K, Lyons KE, et al. Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Neurology 1996; 46:1156-7.
92. Higgins JJ, Litvan I, Pho LT, Li W, Nee LE. Progressive supranuclear palsy is a recessive disorder in linkage disequilibrium with the T and not the α-synuclein gene. Neurology. In press.
93. Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem 1994;62:1631-4.
94. Sian J, Dexter DT, Lees AJ, et al. Alterations in gluthathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:333-4.
95. Loeffler DA, LeWitt PA, Juneau PL, et al. Increased regional brain concentrations of ceruloplasmin in neurodegenentive disorders. Brain Res 1996;738:265-74.
96. Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Ann Neurol 1996;40:139-48.